The chemotherapy-free regimen of Brukinsa and rituximab demonstrated significant progression free survival gains over standard chemoimmunotherapy.
Vistagen plans to meet with the FDA to discuss a long-term registrational pathway, intending to combine positive data from ...
The Baby-COMET study evaluated avalglucosidase alfa (40mg/kg IV every other week for 52 weeks) in 17 infants with infantile-onset Pompe disease.
Backed by data from the phase 3 SatraGO trials, satralizumab has the potential to offer patients a convenient, at-home treatment option.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results